文献速递神经创伤神经重症

口服格列本脲对中重度创伤性脑损伤患者脑挫伤体积和功能结局的影响:一项随机双盲安慰剂对照临床试验

Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
PubMed 文献 · World Neurosurg · 2017-02-07

该随机双盲安慰剂对照试验在伊朗南部一家一级创伤中心纳入66例中重度创伤性脑损伤且脑挫伤体积<30 mL的患者,比较口服格列本脲10 mg每日一次共10天与安慰剂对脑挫伤体积和3个月功能结局的影响。格列本脲组挫伤从首次至第二次及首次至第三次的扩张率均显著低于安慰剂组,但两组功能结局(GOS、mRS、DRS)无显著差异。

要点

  • 格列本脲组挫伤首次至第二次扩张率显著低于安慰剂组(P<0.001)。
  • 格列本脲组挫伤首次至第三次扩张率显著低于安慰剂组(P=0.003)。
  • 两组3个月GOS、mRS、DRS功能结局无显著差异。

核心结论

  • 口服格列本脲与中重度创伤性脑损伤伴脑挫伤患者的挫伤扩张率降低相关。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,2015年5月至2016年8月在伊朗南部一家一级创伤中心开展,纳入66例中度(GCS 9-12分)至重度(GCS 5-8分)创伤性脑损伤且脑挫伤体积<30 mL的患者,排除需手术干预者。

主要发现

  • 格列本脲组与安慰剂组在基线、第3天和第7天挫伤体积无显著差异。
  • 格列本脲组首次至第二次挫伤扩张率显著低于安慰剂组(P<0.001)。
  • 格列本脲组首次至第三次挫伤扩张率显著低于安慰剂组(P=0.003)。
  • 两组在3个月时GOS、mRS和DRS评估的功能结局无显著差异。

关键数值与推荐

  • 格列本脲组29例接受10 mg口服格列本脲每日一次共10天,安慰剂组23例接受同剂量安慰剂。
  • 脑挫伤体积通过螺旋薄层(1 mm层厚)脑CT在0、3、7天进行 volumetric 测量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigated effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. METHODS: A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9-12) to severe (Glasgow Coma Scale score 5-8) traumatic brain injury and brain contusions of <30 mL volume was conducted from May 2015 to August 2016 in a Level I trauma center in southern Iran. Patients who required surgical intervention were excluded. Patients were randomly assigned to receive 10 mg oral glibenclamide daily for 10 days (n = 29) or placebo in the same dosage (n = 23). Brain contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. RESULTS: There was no significant difference between the 2 study groups in baseline, day 3, and day 7 contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry (P < 0.001). Similarly, the first to third expansion ratio was significantly lower in the glibenclamide group compared with placebo (P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. CONCLUSIONS: Oral glibenclamide is associated with decreased contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral contusions.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Khalili H, Derakhshan N, Niakan A, et al. Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial. World Neurosurg. 2017. PMID: 28185976. doi:10.1016/j.wneu.2017.01.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。